Jenna Geohagan, MD
Family Medicine · Seminole, OKNPI 1760879076
Payments from drug & device makers
Across 294 payments — averaging $15.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- AstraZeneca$720
- Lilly USA, LLC$598
- Amgen$359
- Novo Nordisk$240
- Amarin Pharma, Inc.$176
- plus $1K from 25 others
What the payments were for
- Food & beverage$4,570100%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 80 | $1,227 |
| AstraZeneca | 48 | $720 |
| Lilly USA, LLC | 40 | $598 |
| Amgen | 24 | $359 |
| Novo Nordisk | 15 | $240 |
| Amarin Pharma, Inc. | 10 | $176 |
| Pfizer | 11 | $172 |
| Novartis | 10 | $152 |
| GSK | 11 | $150 |
| Sumitomo Pharma America, Inc. | 7 | $136 |
| Sanofi-aventis U.S. LLC | 5 | $96 |
| Mylan Specialty L.p. | 3 | $65 |
| Xeris Pharmaceuticals, Inc. | 3 | $57 |
| Otsuka America Pharmaceutical, Inc. | 3 | $54 |
| Boehringer Ingelheim | 3 | $52 |
| Sunovion Pharmaceuticals Inc. | 2 | $39 |
| Astellas Pharma US Inc | 2 | $39 |
| Merck | 2 | $29 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $28 |
| Aytu Biopharma, Inc. | 2 | $26 |
| Lundbeck LLC | 1 | $24 |
| Radius Health, Inc. | 1 | $21 |
| Sanofi Pasteur Inc. | 1 | $16 |
| Collegium Pharmaceutical, Inc. | 1 | $16 |
| Sun Pharmaceutical Industries Inc. | 1 | $16 |
| Exact Sciences | 1 | $16 |
| Esperion Therapeutics, Inc. | 1 | $14 |
| Bayer | 1 | $14 |
| Dexcom, Inc. | 1 | $14 |
| Organon | 1 | $11 |
| Teva Pharmaceuticals USA, Inc. | 1 | $11 |
How this compares
$4,585 in reported general payments places this provider in the 85th percentile of 1,730 family medicine providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 180 | $232,821 |
| MounjaroTirzepatide | 172 | $219,568 |
| OzempicSemaglutide | 131 | $175,994 |
| ProliaDenosumab | 52 | $87,983 |
| XareltoRivaroxaban | 55 | $86,926 |
| EliquisApixaban | 57 | $67,634 |
| GemtesaVibegron | 62 | $63,274 |
| TradjentaLinagliptin | 37 | $56,534 |
| Invega SustennaPaliperidone Palmitate | 13 | $52,315 |
| EntrestoSacubitril/Valsartan | 29 | $40,542 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 35 | $34,777 |
| TrulicityDulaglutide | 22 | $33,979 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 18 | $32,008 |
| RybelsusSemaglutide | 14 | $28,584 |
| VraylarCariprazine Hcl | 13 | $24,386 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $598 | $253,547194 claims |
| AstraZenecaFarxiga | $720 | $232,821180 claims |
| Novo NordiskOzempic, Rybelsus | $240 | $204,578145 claims |
| Boehringer IngelheimTradjenta, Jardiance, Jentadueto, Synjardy Xr | $52 | $99,11882 claims |
| AmgenProlia | $359 | $87,98352 claims |
| PfizerEliquis | $172 | $67,63457 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $136 | $63,27462 claims |
| NovartisEntresto | $152 | $40,54229 claims |
| GSKTrelegy Ellipta | $150 | $34,77735 claims |
| AbbVieVraylar | $1,227 | $24,38613 claims |
| Astellas Pharma US IncMyrbetriq | $39 | $23,28619 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,730 family medicine providers in Oklahoma.
Other family medicine in Seminole
- Carl GriffinOklahoma City$28.2M
- Lisa ConneryNorman$15.6M
- Kyle RicknerYukon$14.7M
- Robert LockwoodYukon$8.6M
- Steven CoxNorman$6.9M
- Alexander FrankOklahoma City$3.1M
- Rachel AndersonNorman$2.8M
- Robert WestcottLindsay$1.6M
- Charles LunnOklahoma City$1.4M
- Jeffrey ChasteenTulsa$820K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.